[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR102198A1 - Proceso para reducir partículas subvisibles en una formulación farmacéutica - Google Patents

Proceso para reducir partículas subvisibles en una formulación farmacéutica

Info

Publication number
AR102198A1
AR102198A1 ARP150103235A ARP150103235A AR102198A1 AR 102198 A1 AR102198 A1 AR 102198A1 AR P150103235 A ARP150103235 A AR P150103235A AR P150103235 A ARP150103235 A AR P150103235A AR 102198 A1 AR102198 A1 AR 102198A1
Authority
AR
Argentina
Prior art keywords
protein
subvisible particles
fatty acid
acid ester
composition
Prior art date
Application number
ARP150103235A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR102198A1 publication Critical patent/AR102198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicación 1: Una composición que comprende (a) una proteína, (b) un éster de ácido graso intacto, y (c) (i) no más de 400 partículas subvisibles de 10 mm o más de diámetro, o (ii) no más de 10.000 partículas subvisibles de 2 mm o más de diámetro. Reivindicación 2: La composición de acuerdo con la reivindicación 1, en donde la proteína es un anticuerpo. Reivindicación 4: La composición de acuerdo con cualquiera de las reivindicaciones 1 - 3, en donde el éster de ácido graso es un mono o di-éster de ácido graso de polioxietilén sorbitán o isosorbida. Reivindicación 15: Un proceso para elaborar una formulación de proteína estable que comprende la etapa de llenar un recipiente con una sustancia farmacológica formulada, que está esencialmente libre de actividad de esterasa y que contiene una proteína y un éster de ácido graso, en donde la sustancia farmacológica formulada está esencialmente libre de partículas subvisibles. Reivindicación 16: El proceso de acuerdo con la reivindicación 15, en donde la sustancia farmacológica formulada se obtiene poniendo en contacto una composición, que contiene la proteína y una esterasa, con un medio de interacción hidrofóbica, y recolectando la proteína.
ARP150103235A 2014-10-09 2015-10-07 Proceso para reducir partículas subvisibles en una formulación farmacéutica AR102198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462061797P 2014-10-09 2014-10-09

Publications (1)

Publication Number Publication Date
AR102198A1 true AR102198A1 (es) 2017-02-08

Family

ID=54364685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103235A AR102198A1 (es) 2014-10-09 2015-10-07 Proceso para reducir partículas subvisibles en una formulación farmacéutica

Country Status (4)

Country Link
US (2) US10342876B2 (es)
AR (1) AR102198A1 (es)
TW (1) TW201628649A (es)
WO (1) WO2016057739A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
EP4183414A1 (en) 2016-08-16 2023-05-24 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
WO2018039499A1 (en) * 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US11254753B2 (en) 2016-10-06 2022-02-22 Glaxosmithkline Intellectual Property Development Limited Antibodies with reduced binding to process impurities
IL295211B2 (en) 2016-10-25 2024-09-01 Regeneron Pharma Methods and systems for analysis of chromatography data
KR20200054980A (ko) * 2017-09-19 2020-05-20 리제너론 파아마슈티컬스, 인크. 입자 형성을 감소시키는 방법 및 그것에 의해 형성된 조성물
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
AU2019299321A1 (en) 2018-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Use of multiple hydrophobic interaction chromatography for preparing a polypeptide from a mixture
SG11202109004TA (en) 2019-03-05 2021-09-29 Regeneron Pharma Human serum albumin in formulations
WO2020227126A1 (en) * 2019-05-03 2020-11-12 Lonza Ltd Determination of contaminants in cell-based products with flow imaging microscopy
US20230077205A1 (en) * 2020-01-29 2023-03-09 Merck Sharp & Dohme Llc Methods of separating host cell lipases from an anti-lag3 antibody production
KR20220147626A (ko) * 2020-02-27 2022-11-03 리제너론 파아마슈티컬스, 인크. 약물 제형 중 폴리소르베이트의 분해 감소 방법
TW202221008A (zh) 2020-08-07 2022-06-01 瑞士商赫孚孟拉羅股份公司 製備蛋白質組成物之方法
IL310285A (en) 2021-08-13 2024-03-01 Biotest Ag Fibrinogen preparations and preparation methods
TW202409060A (zh) 2022-05-02 2024-03-01 美商再生元醫藥公司 用於降低脂酶活性之方法
TW202406572A (zh) 2022-05-02 2024-02-16 美商再生元醫藥公司 抗介白素－４受體（ｉｌ－４ｒ）抗體調配物
WO2024184444A1 (en) * 2023-03-08 2024-09-12 Immunovant Sciences Gmbh High concentration protein formulations with polysorbate excipients and methods of making the same
CN116563245B (zh) * 2023-05-11 2024-09-27 中国食品药品检定研究院 一种基于粒径大小的亚可见颗粒计算方法、系统及设备
CN116563244B (zh) * 2023-05-11 2024-04-23 中国食品药品检定研究院 一种亚可见颗粒质控方法、系统及设备

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190864A (en) 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US4801726A (en) 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US4937188A (en) 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US5412083A (en) 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO1996025425A1 (en) 1995-02-16 1996-08-22 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0964057B1 (en) 1998-05-11 2004-12-22 Tosoh Corporation Method for separating nucleic acids by means of liquid chromatography
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US7101982B2 (en) 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
US8840884B2 (en) 2002-02-14 2014-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
CA2498725C (en) 2002-09-13 2014-07-08 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
WO2004087761A1 (ja) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
CA2530388A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
EP1687328B1 (en) 2003-10-24 2010-03-31 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
EP1718386A1 (en) 2004-02-27 2006-11-08 GE Healthcare Bio-Sciences AB A process for the purification of antibodies
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US7795405B2 (en) 2004-08-09 2010-09-14 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US20060027454A1 (en) 2004-08-09 2006-02-09 Dinovo Augustine Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
WO2006043895A1 (en) 2004-10-21 2006-04-27 Ge Healthcare Bio-Sciences Ab A method of antibody purification
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
US20080299671A1 (en) 2005-12-02 2008-12-04 Ge Healthcare Bio-Sciences Ab Hydrophobic Interaction Chromatography
AU2007229554A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
US7863426B2 (en) 2006-04-05 2011-01-04 Abbott Biotechnology Ltd. Antibody purification
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
WO2008028974A1 (en) 2006-09-08 2008-03-13 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
US20080299545A1 (en) 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
DK2252952T3 (da) 2008-01-25 2019-06-11 Biogen Ma Inc Automatiseret system og fremgangsmåde til monitorering af ydeevnen for en kromatografisøjle samt anvendelser deraf
JP5635509B2 (ja) 2008-08-15 2014-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド クロマトグラフィーカラムの性能を評価するための方法
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
TWI610936B (zh) 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
EP2346897A2 (en) 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
SG175188A1 (en) 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
LT3444335T (lt) 2009-06-16 2021-07-26 Genzyme Corporation Patobulinti rekombinantinių aav vektorių gryninimo būdai
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
MX2012004711A (es) 2009-10-20 2012-05-23 Abbott Lab Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a.
US8246833B2 (en) 2009-12-17 2012-08-21 Ge Healthcare Bio-Sciences Ab Chromatography column and maintenance method
AU2011214361C1 (en) 2010-02-12 2016-01-14 Dpx Holdings B.V. Single unit antibody purification
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US20140288278A1 (en) 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
MX350355B (es) 2011-11-14 2017-09-04 Regeneron Pharma Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
PT2791176T (pt) 2011-12-15 2018-11-05 Prestige Biopharma Pte Ltd Um método de purificação de anticorpos
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
TW201348246A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014025771A2 (en) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Methods and compositions for inactivating enveloped viruses
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
JP6326066B2 (ja) * 2012-12-20 2018-05-16 メディミューン，エルエルシー 凝集プロファイルが改善されている液状抗体製剤
SG10202011130TA (en) 2013-03-08 2020-12-30 Genzyme Corp Continuous purification of therapeutic proteins
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2899308C (en) 2013-03-14 2017-04-18 Abbvie Inc. Low acidic species adalimumab compositions and uses thereof
EP2970378B1 (en) 2013-03-15 2021-05-26 Biogen MA Inc. Hydrophobic interaction protein chromatography under no-salt conditions
EP3754012A1 (en) 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
US9150938B2 (en) 2013-06-12 2015-10-06 Orochem Technologies, Inc. Tagatose production from deproteinized whey and purification by continuous chromatography
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
CN105848746B (zh) 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015061526A1 (en) 2013-10-25 2015-04-30 Medimmune, Llc Antibody purification
US10115576B2 (en) 2013-12-12 2018-10-30 Waters Technologies Corporation Method and an apparatus for analyzing a complex sample
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
JP2017536391A (ja) 2014-12-02 2017-12-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−６ｒアンタゴニストを投与することによってドライアイ疾患を治療するための方法
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
WO2017112775A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
MX2018007756A (es) 2015-12-22 2018-08-09 Regeneron Pharma Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
BR112018075667B1 (pt) 2016-06-14 2024-02-20 Biogen Ma, Inc Métodos para separar um oligonucleotídeo alvo de uma mistura contendo o oligonucleotídeo alvo e uma impureza relacionada com o produto
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
WO2019040671A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
JP7462566B2 (ja) 2018-03-16 2024-04-05 ブリストル－マイヤーズ スクイブ カンパニー タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
WO2019178495A1 (en) 2018-03-16 2019-09-19 Biogen Ma Inc. Methods for purifying recombinant adeno-associated viruses
US20210009632A1 (en) 2018-03-29 2021-01-14 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
WO2019246153A1 (en) 2018-06-19 2019-12-26 Bristol-Myers Squibb Company Methods of purifying proteins using chromatography
AU2019299321A1 (en) 2018-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Use of multiple hydrophobic interaction chromatography for preparing a polypeptide from a mixture
US20220267369A1 (en) 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
EP3837281A1 (en) 2018-08-15 2021-06-23 Bristol-Myers Squibb Company Protein fragmentation control strategy by re-oxidation in downstream chromatography
CN113301922A (zh) 2018-11-05 2021-08-24 百时美施贵宝公司 用于纯化聚乙二醇化蛋白的方法
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
CN113646630B (zh) 2019-03-29 2024-05-07 百时美施贵宝公司 测量色谱树脂的疏水性的方法
CN114173827A (zh) 2019-06-28 2022-03-11 武田药品工业株式会社 腺相关病毒纯化方法

Also Published As

Publication number Publication date
TW201628649A (zh) 2016-08-16
US20160101181A1 (en) 2016-04-14
WO2016057739A1 (en) 2016-04-14
US10342876B2 (en) 2019-07-09
US12070502B2 (en) 2024-08-27
US20190231877A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
AR103173A1 (es) Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CO2018002026A2 (es) Composiciones de insulina de rápida acción
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
MY166210A (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
EA201590730A1 (ru) Способ и стероидная композиция для местного применения
AR098168A1 (es) Formulación estable de insulina glulisina
AR109685A1 (es) Composiciones de nanopartículas y métodos para fabricarlas y usarlas
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EA201491471A1 (ru) Состав, содержащий антитело против ил-17
CL2015003596A1 (es) Formulación de liberación modificada
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
PH12019500024A1 (en) Pharmaceutical compositions
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
BR112013027487A2 (pt) Combinações de substâncias ativas e formulações cosméticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure